who is not a good candidate for semaglutide patients with #obesity, semaglutide, glucagon-like peptide-1 receptor agonist, approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg The Pros and Cons of

Colorectal Polyps or Colorectal Cancer 6

Overcoming Challenges in Telehealth Adoption While telehealth offers tremendous benefits, its adoption does come with challenges

And if not, what else could be to blame

In the current study, the treatment group demonstrated a statistically significant degree of average weight loss (3.1%) at 12 months, with subgroup analyses revealing varying degrees of weight reduction across demographic groups

Nelson CJ, Diblasio C, Kendirci M et al: The chronology of depression and distress in men with Peyronie's disease

Emerging evidence suggests GLP-1 diabetes and obesity drugs may benefit the mind as well as the body